Godavari Biorefineries Surges 5.7% to ₹278 After European Patent Approval for Novel Anti-Cancer Compounds

Mumbai, 17 October 2025: Shares of Godavari Biorefineries Ltd (NSE: GODAVARIB) continued their strong momentum on Friday, rising 5.7% to ₹278 in early trade, following the company’s confirmation of a European patent grant for its innovative anti-cancer compounds. The stock had earlier opened at ₹289.30, touched an intraday high of ₹289.30, and recorded a low of ₹270, reflecting persistent market interest after the positive development.

Godavari Biorefineries Ltd, headquartered in India, operates across bio-based chemicals, renewable energy, and FMCG intermediates, with growing involvement in specialty bio-products. Listed on both NSE and BSE, the company became part of the Nifty IPO Index following its listing on 30 October 2024. The European patent approval further strengthens its position in the life sciences innovation domain while complementing its existing sustainable business verticals.

European Patent Approval Propels Stock Rally to 52-Week Momentum

The surge in Godavari Biorefineries’ shares comes on the back of its European patent titled “Compounds for the Inhibition of Unregulated Cell Growth”, which protects a series of novel chemical compounds targeting cancer stem cells. These compounds have demonstrated potential in treating breast and prostate cancers, reinforcing the company’s strategic focus on bio-innovation within the life sciences sector.

The patent marks a key milestone in the company’s Anti-Cancer Research segment, expanding its footprint beyond traditional bio-based chemicals, renewable energy, and FMCG intermediates. The recognition underscores the company’s growing emphasis on specialty and sustainable product segments, enhancing its intellectual property portfolio.

Market Activity Reflects Positive Investor Interest Post-Patent Announcement

At 10:09 a.m. IST, trading volumes remained active, with the market cap reaching ₹1,420 crore. The stock has experienced a significant year-on-year increase, moving from a 52-week low of ₹145 to touch highs closer to ₹408.60, highlighting the impact of strategic milestones on its valuation trajectory.

The recent price action indicates sustained investor attention in response to strong research and innovation credentials, with the opening at ₹289.30 and intraday fluctuations showing robust buy activity despite market volatility.

The European patent grant underscores the increasing role of intellectual property in driving corporate growth and recognition. Companies advancing proprietary research in life sciences and specialty chemicals can leverage such approvals to enhance their technological footprint and expand their strategic market positioning.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations